Company: SWKH
Filing Date: 2025-11-06
Form Type: 10-Q
Source: 0001628280-25-050155
Chunk: 86

Company: SWK Holdings Corp
Filing Date: 2025-11-06
Form: 10-Q
Item: Part I, Item 8
Chunk 86
---
 table below provides an overview of our outstanding finance receivables transactions as of and for the three and nine months ended September 30, 2025 (in thousands, except rate, share and per share data):

Revenue RecognizedRoyalty PurchasesLicensed TechnologyFunded AmountGAAP BalanceQ3 2025Year-to-DateBesivance® (1) Ophthalmic antibiotic$6,000 $— $— $2 Forfivo XL® (6)Depressive disorder treatment6,000 — — 506 Coflex®/Kybella® (6)Spinal stenosis/submental fullness4,350 — — 48 Cambia® (6)NSAID migraine treatment8,500 — — 98 Duo Royalty (6)Japanese Women's health/cystic fibrosis15,353 — — 591 Immune Globulin (6)Immune Globulin Therapeutics 14,100 — — 443 Relief (6)Rare Disease Portfolio7,701 — — 336 Best ABT, Inc.(2), (3)Oncology diagnosis 5,784 2,347 — — Flowonix Medical, Inc.(2), (3), (4)Drug delivery device 12,455 6,633 — — Ideal Implant, Inc.(2), (3)Aesthetics 4,025 2,522 — — Iluvien® (7)Diabetic macular edema16,501 — — 519 Revenue RecognizedTerm LoansTypeMaturity DatePrincipalGAAP BalanceRateQ3 2025Year-to-Date4Web, Inc.First lien12/31/27$19,486 $23,037 12.8%$1,226 $3,083 AOTI, Inc.First lien02/15/2919,478 19,623 13.0%658 1,411 Elutia, Inc.First lien08/10/2722,074 27,372 11.0%2,335 4,161 Biotricity, Inc.First lien02/15/2713,846 14,413 11.5%660 2,004 CDMO ManufacturerFirst lien09/13/275,000 5,491